EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

AI-based IsAb2.0 for antibody design

Tianjian Liang, Ze-Yu Sun iD, Margaret G Hines, Kerri Jo Penrose, Yixuan Hao, Xiaojie Chu, John W Mellors, Dimiter S Dimitrov, Xiang-Qun Xie, Wei Li, Zhiwei Feng iD

Briefings in Bioinformatics · 25.07.2024 · 25 (5)

DOI: 10.1093/bib/bbae445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 16.09.2024. Verfasst von Tianjian Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, Pharmacometrics & System Pharmacology PharmacoAnalytics, Sch…. Hauptthemen laut MEDLINE: Artificial Intelligence, Protein Engineering. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS, I4C 2.0: Immunotherapy for Cure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic antibody design has garnered widespread attention, highlighting its interdisciplinary importance. Advancements in technology emphasize the critical role of designing nanobodies and humanized antibodies in antibody engineering. However, current experimental methods are costly and time-consuming. Computational approaches, while progressing, faced limitations due to insufficient structural data and the absence of a standardized protocol. To tackle these challenges, our lab previously developed IsAb1.0, an in silico antibody design protocol. Yet, IsAb1.0 lacked accuracy, had a complex procedure, and required extensive antibody bioinformation. Moreover, it overlooked nanobody and humanized antibody design, hindering therapeutic antibody development. Building upon IsAb1.0, we enhanced our design protocol with artificial intelligence methods to create IsAb2.0. IsAb2.0 utilized AlphaFold-Multimer (2.3/3.0) for accurate modeling and complex construction without templates and employed the precise FlexddG method for in silico antibody optimization. Validated through optimization of a humanized nanobody J3 (HuJ3) targeting HIV-1 gp120, IsAb2.0 predicted five mutations that can improve HuJ3-gp120 binding affinity. These predictions were confirmed by commercial software and validated through binding and neutralization assays. IsAb2.0 streamlined antibody design, offering insights into future techniques to accelerate immunotherapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceProtein EngineeringHumansSingle-Domain AntibodiesHIV Envelope Protein gp120Drug DesignComputer Simulation

Stichwörter der Autor:innen

AlphaFold-MultimerHIV-1 nanobodyIsAbantibody designdeep learninghumanized antibody

Substanzen

Single-Domain AntibodiesHIV Envelope Protein gp120

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy, University of Pittsburgh, 335 Sutherland Drive, Pitts…
  • National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, 3501 Terrace St, Pittsburgh, PA 15261, United States.
  • Drug Discovery Institute, University of Pittsburgh, 3501 Terrace St, Pittsburgh, PA 15261, United States.
  • Department of Computational Biology, School of Medicine, University of Pittsburgh, 3420 Forbes Avenue, Pittsburgh, PA 15261, United States.
  • Department of Structural Biology, School of Medicine, University of Pittsburgh, 3501 Fifth Ave, Pittsburgh, PA 15261, United States.
  • Division of Infectious Diseases, Department of Medicine, Center for Antibody Therapeutics, School of Medicine, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA, United States.

ORCID-Profile: Ze-Yu Sun, Zhiwei Feng

Förderung

  • NIAID NIH HHS
  • NIDA NIH HHS
  • I4C 2.0: Immunotherapy for Cure
  • National Institutes of Health National Institute on Drug Abuse

Zitieren

APA

Liang, T., Sun, Z. Y., Hines, M. G., Penrose, K. J., Hao, Y., Chu, X., Mellors, J. W., Dimitrov, D. S., Xie, X. Q., Li, W., & Feng, Z. (2024). AI-based IsAb2.0 for antibody design. Briefings in Bioinformatics, 25(5). https://doi.org/10.1093/bib/bbae445

Vancouver

Liang T, Sun ZY, Hines MG, Penrose KJ, Hao Y, Chu X, et al. AI-based IsAb2.0 for antibody design. Briefings in Bioinformatics. 2024;25(5). doi:10.1093/bib/bbae445

BibTeX
@article{Liang2024,
  author = {Liang, Tianjian and Sun, Ze-Yu and Hines, Margaret G and Penrose, Kerri Jo and Hao, Yixuan and Chu, Xiaojie and Mellors, John W and Dimitrov, Dimiter S and Xie, Xiang-Qun and Li, Wei and Feng, Zhiwei},
  title = {AI-based IsAb2.0 for antibody design},
  journal = {Briefings in Bioinformatics},
  year = {2024},
  volume = {25},
  number = {5},
  doi = {10.1093/bib/bbae445}
}
Kostenlos starten →